A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

February 7, 2023

Study Completion Date

September 20, 2023

Conditions
Anal Cancer
Interventions
DRUG

MPDL3280A

MPDL3280A administered every 2 weeks at 800 mg for 12 months.

DRUG

mDCF

8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5-FU at 1200 mg/m2/day for 2 days) every 2 weeks

Trial Locations (31)

7514

Hôpital Saint Antoine, Paris

25000

CHRU Jean Minjoz, Besançon

Unknown

Clinique de l'Europe, Amiens

Institut Sainte Catherine, Avignon

CHU Bordeaux - Hôpital Haut Lévêque, Bordeaux

Centre François Baclesse, Caen

Hôpitaux Civils de Colmar, Colmar

Clinique des Cèdres, Cornebarrieu

GHPSO Creil, Creil

Centre Georges François Leclerc, Dijon

Institut Hospitalier Franco-Britannique, Levallois-Perret

Centre Oscar Lambert, Lille

Centre Léon Bérard, Lyon

Hôpital Jean Mermoz, Lyon

CHU Timone, Marseille

Hopital Montbéliard, Montbéliard

ICM Val d'Aurelle, Montpellier

CHU Nantes, Nantes

Centre Antoine Lacassagne, Nice

Groupe Hospitalier Diaconesses Crois Saint Simon, Paris

Groupe Hospitalier Saint Joseph, Paris

Hôpital Européen Georges Pompidou, Paris

Hôpital Henri Mondor, Paris

Hôpital saint Louis, Paris

Insitut Curie, Paris

Centre CARIO, Plérin

CHU Poitiers, Poitiers

CHU Robert Debré Reims, Reims

CH Saint Quentin, Saint-Quentin

Centre Paul Strauss, Strasbourg

CHU Tours, Tours

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER

NCT03519295 - A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma | Biotech Hunter | Biotech Hunter